Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Miglietta

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
The Lancet. Oncology|July 12, 2021
HER2: a never ending storyMaria Vittoria Dieci, Federica Miglietta
Expert Review of Anticancer Therapy|August 15, 2023
How can we refine the prognostic stratification of triple-negative breast cancer?Federica Miglietta, Maria Vittoria Dieci
The Lancet. Digital Health|December 11, 2025
Artificial intelligence and tumour-infiltrating lymphocytes in breast cancer: bridging innovation and feasibility towards clinical utilityFederica Miglietta, Maria Vittoria Dieci
Cells|January 27, 2021
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical ImplicationsMaria Vittoria Dieci, Federica Miglietta, Valentina Guarneri
Bioinformatics (Oxford, England)|July 22, 2024
ALLSTAR: Inference of ReliAble CausaL RuLes between Somatic MuTAtions and CanceR PhenotypesDario Simionato, Antonio Collesei, Federica Miglietta, et al.
Breast (Edinburgh, Scotland)|May 31, 2024
Managing sexual health challenges in breast cancer survivors: A comprehensive reviewLinda Cucciniello, Federica Miglietta, Valentina Guarneri, et al.
Cancer Treatment Reviews|July 5, 2020
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptorsMaria Vittoria Dieci, Federica Miglietta, Gaia Griguolo, et al.
Cancers|September 25, 2019
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing PerspectivesLuisa Carbognin, Federica Miglietta, Ida Paris, et al.
Cancer Treatment Reviews|April 8, 2016
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?Maria Vittoria Dieci, Gaia Griguolo, Federica Miglietta, et al.
The Oncologist|August 25, 2019
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive ValueFederica Miglietta, Gaia Griguolo, Valentina Guarneri, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|July 12, 2021
HER2: a never ending storyMaria Vittoria Dieci, Federica Miglietta
Expert Review of Anticancer Therapy|August 15, 2023
How can we refine the prognostic stratification of triple-negative breast cancer?Federica Miglietta, Maria Vittoria Dieci
The Lancet. Digital Health|December 11, 2025
Artificial intelligence and tumour-infiltrating lymphocytes in breast cancer: bridging innovation and feasibility towards clinical utilityFederica Miglietta, Maria Vittoria Dieci
Cells|January 27, 2021
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical ImplicationsMaria Vittoria Dieci, Federica Miglietta, Valentina Guarneri
Bioinformatics (Oxford, England)|July 22, 2024
ALLSTAR: Inference of ReliAble CausaL RuLes between Somatic MuTAtions and CanceR PhenotypesDario Simionato, Antonio Collesei, Federica Miglietta, et al.
Breast (Edinburgh, Scotland)|May 31, 2024
Managing sexual health challenges in breast cancer survivors: A comprehensive reviewLinda Cucciniello, Federica Miglietta, Valentina Guarneri, et al.
Cancer Treatment Reviews|July 5, 2020
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptorsMaria Vittoria Dieci, Federica Miglietta, Gaia Griguolo, et al.
Cancers|September 25, 2019
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing PerspectivesLuisa Carbognin, Federica Miglietta, Ida Paris, et al.
Cancer Treatment Reviews|April 8, 2016
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?Maria Vittoria Dieci, Gaia Griguolo, Federica Miglietta, et al.
The Oncologist|August 25, 2019
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive ValueFederica Miglietta, Gaia Griguolo, Valentina Guarneri, et al.
Pageof 8